Viking Therapeutics announced on March 11, 2025, that it has signed a broad, multi-year manufacturing agreement with CordenPharma to support the commercialization of its VK2735 program for obesity. This agreement covers both the active pharmaceutical ingredient (API) and final finished product supply for both subcutaneous and oral formulations of VK2735.
The agreement secures dedicated capacity for the annual manufacture of multiple metric tons of VK2735 API. It also provides significant fill/finish capacity, including 100 million autoinjectors and an additional 100 million vial/syringe products for the subcutaneous formulation, as well as over 1 billion oral tablets annually. These capacities are expandable at Viking's option.
In exchange for this dedicated capacity, Viking will make prepayments totaling $150 million between 2025 and 2028, which will be credited against future orders. This strategic move addresses potential manufacturing scalability risks, a known challenge in the GLP-1 space, and signals the company's confidence in VK2735's potential to become a multi-billion-dollar annual product opportunity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.